News

ecancer symposium at IMPAKT 2017: The coming of age for CDK 4/6 inhibitors

12 Apr 2017
ecancer symposium at IMPAKT 2017: The coming of age for CDK 4/6 inhibitors

Invitation to all IMPAKT 2017 delegates

The ecancer team is hosting a special educational event at the forthcoming IMPAKT 2017 Breast Cancer Conference in Brussels on Friday 5 May. 

The satellite symposium will give you the latest emerging evidence on CDK 4/6 inhibitors and new treatment options for metastatic breast cancer patients. 

Free to all delegates attending IMPAKT, the event will be chaired by Giuseppe Curigliano from the European Institute of Oncology, Milan, Italy.

Speakers include Nicholas Turner from the Royal Marsden in the UK, and IMPAKT Scientific Chair, Sibylle Loibl, from the German Breast Group.

The event will be interactive - as well as taking your questions, we will be asking you to vote using on a series of topics using handheld devices. 

Agenda

  • Welcome and pre-assessment - Giuseppe Curigliano
  • Current clinical data for CDK 4/6 inhibitors in breast cancer - Nicholas Turner
  • Ongoing investigations and future applications - Sibylle Loibl
  • Review of clinical cases and audience questions - All faculty
  • Summary of key points and post-assessment - Giuseppe Curigliano

If you would like more information about this event, please email karen@ecancer.org.

We look forward to seeing you in Brussels.